Concepedia

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

Shawn G. Kwatra, Gil Yosipovitch, Franz J. Legat, Adam Reich, C. Paul, Dagmar Simon, Luigi Naldi, Charles Lynde, Marjolein de Bruin‐Weller, Walter K. Nahm,

New England Journal of Medicine · 2023 · 135 citations · 21 references

DOIFull text

Open access

Abstract

Nemolizumab monotherapy significantly reduced the signs and symptoms of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT04501679; EudraCT number, 2019-004789-17.).

References

21

Lung volumes and forced ventilatory flows

PH Quanjer, G J Tammeling, J. E. Cotes et al. · European Respiratory Journal · 1993 · 5.3K citations · Full text

, , +17

The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease

Milo A. Puhan, Martin Frey, Stefan Büchi et al. · Health and Quality of Life Outcomes · 2008 · 551 citations · Full text

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki et al. · New England Journal of Medicine · 2020 · 339 citations · Full text

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

Sonja Ständer, Gil Yosipovitch, Franz J. Legat et al. · New England Journal of Medicine · 2020 · 267 citations · Full text

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus

Jonathan I. Silverberg, Andreas Pinter, Grażyna Pulka et al. · Journal of Allergy and Clinical Immunology · 2019 · 262 citations · Full text